Ignite Creation Date:
2025-12-24 @ 3:53 PM
Ignite Modification Date:
2025-12-28 @ 7:06 PM
Study NCT ID:
NCT00105092
Status:
COMPLETED
Last Update Posted:
2007-05-01
First Post:
2005-03-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Sponsor:
Eli Lilly and Company